what's good guys
Ive been following this forum for a little over a month and have to thank you all for the information and insight. I figured that id make an account too.
Just to clarify something - TaqMan PCR alone does not have an advantage over xMap, as far as I can tell, with regards to the Biowatch program. TaqMan may be a superiour way of validating results obtained from assays, but it is not up-to-par with xMAP in terms of high through-put capabilities. This is why on PSIDs site, it says that it is used in conjunction with multiplexing.
Whether or not that this combination has the edge over xMAP is the question.
In my opinion, the xMAP technology is theoretically better. However, I can't find enough data to see if it is practically better/technologically possible at the moment. This is why a well-implemented combination system of PSID could be better, especially in the near future, than a theoretically-better, but poorly implemented/incomplete technology.
We will just have to wait and see. My guess is that both companies will get the contract. One can never be "too safe", anyways, in my opinion. The government should take the greatest measures to ensure safety, and this can be done by using two different systems to increase specificity (since they both have their own strengths)
This is what I think, at least.
AI
